Drug Alert: 27 drug samples fail to clear CDSCO test, 1 declared spurious

In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 27 medicine batches for failing to qualify for a random drug sample test for the month of May– 2023, while one drug sample has been declared Spurious.

These drug samples which are declared not of standard quality include Jackson Laboratories' Bupivacaine Heavy (Bupivacaine Hydrochloride in Dextrose Injection USP 4 ml), Alves Healthcare's Doxycycline Capsules IP, Terrace Pharmaceuticals' Teripil -80 (Telmisartan Tablets I.P.), Bengal Chemical and Pharmaceuticals' Ofloxacin and Ornidazole Tablets IP, Zee Laboratories' MONAMOX-CL 625 (Amoxycillin& Potassium Clavulanate Tablets I.P.) and others.

For more details, check out the full story on the link below:

CDSCO Drug Alert: 27 Drug Samples Flagged